/

Cassava Sciences, Inc.

SAVA US

SAVA USCassava Sciences, Inc.

United States Composite

19.64

USD

-1.55

(-7.31%)

-2.32EPS Dil.

-8.47P/E

829.53MMarket Cap

Next Earnings

April 29

Ex-Dividend Date

December 13

Dividend Date

May 10

Held by Insiders

9.14%

Held by Institutions

32.72%

Short % of Float

26.18%

YTD Yield

-11.94%

3Y Yield

-35.99%

5Y Yield

1,737.50%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

1,028

701

951

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

175

150

130

Cash, Cash Equivalents & STI

168

142

121

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

-68.95%

-117.98%

-27.63%

Free Cash Flow

-101.84%

-204.60%

-2.50%

Total Cash Common Dividend

- -

Total Equity

42.81%

90.82%

-39.91%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.09

-0.13

-0.24

-0.35

-0.82

2022

-0.44

-0.48

-0.51

-0.47

-1.90

2023

-0.58

-0.63

-0.61

-0.50

-2.32

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Remi Barbier
Full Time Employees: 29
Sector: Healthcare
Industry: Biotechnology
Address: 6801 N. Capital of Texas Highway Austin TX United States 78731
CIK: 0001069530
Website: www.cassavasciences.com
Business: Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Company News

Yahoo
a month ago
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Yahoo
a month ago
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

Company Description

CEO: Mr. Remi Barbier
Full Time Employees: 29
Sector: Healthcare
Industry: Biotechnology
Address: 6801 N. Capital of Texas Highway Austin TX United States 78731
CIK: 0001069530
Website: www.cassavasciences.com
Business: Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.